ArticleF1000Research
Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target.
Article in F1000Research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04382768 (Extended Compassionate Use Program), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.Bioorganic chemistry · 2021Pooled it
- Bioinformatic Selection of Mannose-Specific Lectins fromLife (Basel, Switzerland) · 2025Article
- SARS-CoV-2 PLChemistryOpen · 2024Article
- In Silico Exploration of CD200 as a Therapeutic Target for COVID-19.Microorganisms · 2024Article
- Zebrafish models of COVID-19.FEMS microbiology reviews · 2023Review
- AnJournal of biomolecular structure & dynamics · 2022Article
- Article
- Evaluating the mitigation strategies of COVID-19 by the application of the COEnvironmental research · 2022Article
- Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach.ChemistryOpen · 2022Article
- Animal models for SARS-CoV-2 infection and pathology.MedComm · 2021Review
- Pigs are not susceptible to SARS-CoV-2 infection but are a model for viral immunogenicity studies.Transboundary and emerging diseases · 2021Article
- A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin.Journal of biomolecular structure & dynamics · 2021Review
- Evidence of a dysregulated vitamin D endocrine system in SARS-CoV-2 infected patient's lung cells.Scientific reports · 2021Article
- Evolution of SARS-CoV-2 virus and assessment of the effectiveness of COVID-19 vaccine.F1000Research · 2021Article
- Virtual screenings of the bioactive constituents of tea, prickly chaff, catechu, lemon, black pepper, and synthetic compounds with the main protease (Mpro) and human angiotensin-converting enzyme 2 (ACE 2) of SARS-CoV-2.Future journal of pharmaceutical sciences · 2021Article
- The SARS-CoV-2 outbreak from a one health perspective.One health (Amsterdam, Netherlands) · 2020Article
- Animal models for COVID-19.Nature · 2020Review
- Coronavirus Disease 2019-COVID-19.Clinical microbiology reviews · 2020Review
- Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a NovelMolecules (Basel, Switzerland) · 2020Article
- COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.Human vaccines & immunotherapeutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel coronavirus recently identified in Wuhan, China (SARS-CoV-2) has expanded the number of highly pathogenic coronaviruses affecting humans. The SARS-CoV-2 represents a potential epidemic or pandemic threat, which requires a quick response for preparedness against this infection. The present report uses the informational spectrum methodology to identify the possible origin and natural host of the new virus, as well as putative therapeutic and vaccine targets. The performed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.